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ABAT is a key enzyme responsible for catabolism of
principal inhibitory neurotransmitter g-aminobutyric
acid (GABA). We report an essential role for ABAT in
a seemingly unrelated pathway, mitochondrial nucle-
oside salvage, and demonstrate that mutations in
this enzyme cause an autosomal recessive neurome-
tabolic disorder and mtDNA depletion syndrome
(MDS). We describe a family with encephalomyo-
pathic MDS caused by a homozygous missense
mutation in ABAT that results in elevated GABA in
subjects’ brains as well as decreased mtDNA levels
in subjects’ fibroblasts. Nucleoside rescue and co-
IP experiments pinpoint that ABAT functions in the
mitochondrial nucleoside salvage pathway to facili-
tate conversionofdNDPs todNTPs.Pharmacological
inhibition of ABAT through the irreversible inhibitor
Vigabatrin caused depletion of mtDNA in photore-
ceptor cells that was prevented through addition of
dNTPs in cell culture media. This work reveals ABAT
as a connection between GABA metabolism and
nucleoside metabolism and defines a neurometa-
bolic disorder that includes MDS.
INTRODUCTION
Mitochondria are essential for maintaining cell physiological
processes that include respiration, apoptosis, and calcium
buffering. The mitochondrial matrix is the site of multiple meta-
bolic processes including carbohydrate, lipid, amino acid,
and nucleoside metabolism. The principal inhibitory neuro-
transmitter g-aminobutyric acid (GABA) is catabolized within
the mitochondrial matrix by GABA transaminase encoded by
4-aminobutyrate aminotransferase (ABAT). Disorders of the
GABAergic system can lead to mood and cognitive dysfunction
as well as seizures and multiple pharmacological compounds
aimed at ameliorating these disorders target this pathway
(Millan et al., 2012; Rogawski and Lo¨scher, 2004; Rudolph
and Mo¨hler, 2014).CeDisturbance of mitochondrial function causes a group of dis-
eases termed primary mitochondrial disorders that can affect
every organ system and have a diverse clinical presentation
(McFarland et al., 2010). One subtype of primary mitochondrial
disorders is caused by a dysfunction in the maintenance of the
mitochondrial genome (mtDNA) characterized by a severe loss
of mtDNA copy number (Suomalainen and Isohanni, 2010).
Clinically, mtDNA depletion syndromes (MDSs) typically present
in encephalomyopathic, hepatocerebral, or myopathic forms.
MDSs are Mendelian autosomal recessive disorders, and the
pathogenic genes responsible play roles in several pathways:
replication of the mitochondrial genome (POLG [Naviaux and
Nguyen, 2004], PEO1 [Sarzi et al., 2007], andMGME1 [Kornblum
et al., 2013]), mitochondrial nucleoside metabolism (SUCLG1
[Ostergaard et al., 2007], SUCLA2 [Elpeleg et al., 2005], DGUOK
[Mandel et al., 2001], and TK2 [Saada et al., 2001]), cytosolic
nucleoside metabolism (TYMP [Nishino et al., 1999] and
RRM2B [Bourdon et al., 2007]), nucleoside translocator
(SLC25A4 [Palmieri et al., 2005]), and functions yet to be deter-
mined (MPV17 [Spinazzola et al., 2006], and FBXL4 [Bonnen
et al., 2013; Gai et al., 2013]).
Humans with genetic mutations leading to ABAT deficiency
are extremely rare (OMIM #613163). Clinical reports describe
two families with biochemically confirmed ABAT deficiency
(Jaeken et al., 1984; Tsuji et al., 2010). The probands in these
families display elevated levels of GABA along with severe psy-
chomotor retardation, intractable seizures, hypotonia, and hy-
perreflexia. All symptomology was attributed to dysfunction of
the GABAergic system.
We report that ABAT provides an essential role in the mito-
chondrial nucleoside salvage pathway, independent of the
GABAergic system, demonstrating that this is a dual-function
enzyme. We present a new case of ABAT deficiency whose clin-
ical presentation includes elevated GABA in the brain as well as
hallmarks of mitochondrial dysfunction in muscle. We show that
genetic and pharmacological inhibition of ABAT in human cells
causes a marked loss of mtDNA copy number. Importantly, we
also demonstrate that expression of each of the pathogenic
ABAT mutations reported in humans with elevated levels of
GABA leads to pronounced mtDNA depletion, thereby proving
the functional consequence of these mutations to be a distur-
bance of mtDNAmaintenance. In addition, we pinpoint precisely
where within the mitochondrial nucleoside salvage pathwayll Metabolism 21, 417–427, March 3, 2015 ª2015 Elsevier Inc. 417
Figure 1. Subjects with ABAT Mutations
Display Brain Abnormalities and Signatures
of Mitochondrial Dysfunction in Muscle
(A)BrainMRI imagesofS1at 5 yearsof age. Image1
shows a T1-weighted sagittal section demon-
strating signs of global cerebral volume loss with
thinning of the corpus callosum and atrophy of
subcortical structures, brainstem, and cerebellar
vermis. Images 2 and3 showT2-weighted axial and
coronal sections demonstrating atrophy anddiffuse
white matter signal abnormalities in the cerebral
hemispheres, prominent atrophy of the thalamus,
and noticeable signal abnormalities in the posterior
limb of the internal capsule and dentate nuclei.
(B) Biochemical assessment of electron transport
chain activity in muscle tissue for S1. Activity is
diminished relative to controls across complex I,
complexes I + III, complex II, complexes II + III,
and complex IV.
(C) Pedigree of Subjects 1 (II-II) and 2 (II-III) shows
Mendelian segregation and recessive inheritance
of mutation ABAT_NM_000663.3 c.631C>T
through the family.
(D) Evaluation of GABA levels in the brain by
in vivo proton magnetic resonance spectroscopy
is shown in mM units with SD. The amount of
GABA in S1 and S2 (black bars) is significantly
elevated over age-matched controls (gray bar).ABAT functions and show that ABAT physically interacts with
other proteins known to function in the metabolism of nucleo-
sides within mitochondria. These discoveries illustrate that care-
ful study of individuals with rare diseases can lead to a greater
understanding of fundamental biological mechanisms.
RESULTS
Mutations in ABAT Identified in Subjects with
Pediatric-Onset Encephalopathy with Neurometabolic
and Mitochondrial Dysfunction
Subject 1 (S1) presented at 3 months of age with infantile
spasms. Her electroencephalogram (EEG) was characterized
by hypsarrhythmia consistent with the diagnosis of West syn-
drome. MRI of the brain was abnormal, showing symmetric
signal abnormalities in several brain regions, including the
posterior limbs of the internal capsule, central aspect of the
cerebral peduncles, dorsal tegmentum and pons, medulla,
and dentate nuclei. She exhibited significant developmental
delay when re-evaluated at 5 years of age, with inability to roll
over or sit unassisted. This re-evaluation also documented
continued seizures despite treatment with anti-epileptic drugs
(AEDs) and significant hypotonia with hyperreflexia. Repeat
MRI of the brain at 5 years of age showed progressive brain at-
rophy with substantial thalamic atrophy in addition to moderate
thinning of both the corpus callosum and brainstem (Figure 1A)
and ophthalmological exam was indicative of cortical visual
impairment.
Muscle biopsy was performed to investigate a possible
mitochondrial disorder, revealing mild variation of fiber size
with rare, large mitochondria of irregular shape; oxidative
enzyme reactions including NADH-TR, SDH, and cytochrome c
oxidase (COX) were reported as normal (no sequential COX/418 Cell Metabolism 21, 417–427, March 3, 2015 ª2015 Elsevier Inc.SDH reaction was performed) with a suggestion of an increase
in subsarcolemmal enzyme activities. Electron microscopy sug-
gested increased glycogen and lipid droplets. Respiratory chain
studies showed significant deficiencies with complexes I, II III,
and IV displaying activities of less than 35% of control (Fig-
ure 1B). Citrate synthase activity was found elevated to 240%
of control mean (controls 9.57 ± 4.72).
Subject 2 (S2) is the younger brother of S1. He followed a
highly similar course and clinical presentation as his sister, with
psychomotor retardation, intractable seizures, and hypotonia.
He had an abnormal EEG that showed generalized cortical
dysfunction and multifocal cortical irritability, especially from
the right posterior region. At last reporting, age 5 years, he
received no benefit from treatment with AEDs. His first MRI at
age 1.5 years showed generalized atrophy of the right cerebral
hemisphere in addition to signal abnormalities involving bilateral
internal capsules and dentate nuclei. Ophthalmological exami-
nation showed cortical visual impairment.
Exome sequencing of S1 revealed a homozygous missense
variant in ABAT. The variant (ABAT NM_000663.3 c.631C > T;
NP_000654.2 p.Leu211Phe) was not observed in the ExAC
cohort comprised of 61,486 individuals, which includes 5,804
individuals who are attributed as ‘‘American’’ ethnicity. Bio-
informatic analyses revealed strong support for pathogenicity
of this variant with SIFT and PolyPhen2 giving maximum or
‘‘most damaging’’ scores (SIFT = 0, PolyPhen2 = 1). This nucle-
otide position also appears highly evolutionarily conserved with
GERP score of 5.61 and PhyloP score of 2.66 (Table 1). S2
was shown by Sanger sequencing to be homozygous for the
ABAT variant and recessive inheritance was demonstrated with
both parents being heterozygous carriers (Figure 1C). Levels of
ABAT mRNA and protein in fibroblasts from S1 and S2 were
similar to control (Figure S1).
Table 1. In Silico Analysis of ABATMutations Identified in Subjects with Intractable Seizures, Severe Psychomotor Retardation, and
Confirmed Elevated Levels of GABA in the Brain
Gene Subject Genome cDNA Protein SIFT PolyPhen2 GERP++ PhyloP ExAC_AC
ABAT S1, S2 16:8862077_C/T c.631C>T p.Leu211Phe 0.00 1.00 5.61 2.66 0
ABAT S3 16:8862105_G/A c.659G>A p.Arg220Lys 0.01 0.92 5.61 2.66 0
ABAT S3 16:8875217_T/C c.1433T>C p.Leu478Pro 0.00 1.00 5.39 2.04 0
ABAT S4 16:8844355_G/A c.275G>A p.Arg92Gln 0.60 1.00 5.93 2.80 0
ABAT S4 16:8844279-?_8844396+?del c.199-?_316+?del p.Asn67ValfsTer8 – – – – 0
Mutation nomenclature references human genome build HG19, ABAT NM_000663.4 for cDNA and ABAT NP_000654.2 for protein. Subject S4 has a
deletion the removes the fourth coding exon which is approximately 100 base pairs in length, however the boundaries of this mutation are not defined.
ExAC_AC = ExAC cohort Allele Count. These mutations were all deposited into ClinVar.ABAT, also known as GABA-transaminase (GABA-T), catabo-
lizes the neurotransmitter GABA into succinic semialdehyde.
Subjects 1 and 2 show excess GABA in the brain by in vivo pro-
ton magnetic resonance spectroscopy, supporting the notion
that the identified missense variant perturbs function of the
ABAT protein. GABA concentrations in the basal ganglia of S1
(2.9mmol/l) and S2 (3.1 mmol/l) were markedly higher compared
to normal mean values for this age range of 1.1 mmol/l ± 0.3 (Fig-
ure 1D). The catabolism of GABA through the GABA shunt is
known to take place in the mitochondrial matrix, and cellular
localization studies confirmed the specific sub-mitochondrial
localization of ABAT to be the matrix compartment (Figure S2).
Subjects from two unrelated families have been clinically
described in the literature as having ABAT deficiency (Jaeken
et al., 1984; Tsuji et al., 2010). These children showed highly
similar clinical presentation to our subjects with severe psycho-
motor retardation, intractable seizures, hypotonia, and hyperre-
flexia. However, none of the individuals previously reported
as having ABAT deficiency were noted to have mitochondrial
dysfunction, and no testing of mitochondrial biochemical
function was reported. We therefore explored the nature of the
mitochondrial deficiency observed in S1 and S2 and tested if
the previously reported pathogenic ABAT alleles led to mito-
chondrial dysfunction.
Knockdown of ABAT in Healthy Fibroblasts Causes
mtDNA Depletion and Diminished Mitochondrial
Membrane Potential
Two independent shRNA hairpins designed to target the 30 UTR
of ABAT both resulted in a 50% reduction of mRNA transcript
(p < 0.001) and protein levels (Figures 2A and 2B) compared
to non-targeting (NT) control when virally delivered to normal
control fibroblasts. Moreover, this forced reduction of ABAT
expression by each hairpin led to a concomitant 50%
decrease in both mtDNA copy number (p < 0.001) and in the
membrane potential (p < 0.001) compared to NT controls (Fig-
ures 2C and 2D), indicating ABAT is required to maintain these
vital features of mitochondrial integrity and function.
All ABAT Mutations Reported to Cause Elevated Levels
of GABA Cause mtDNA Depletion in Fibroblasts
The family reported here is the third family documented to have
ABAT deficiency with confirmed elevated levels of GABA in the
brain and amolecular diagnosis (Tsuji et al., 2010). Previously re-
ported probands (S3 and S4) were shown to have compoundCeheterozygous variants inABAT (Figure 3A; Table1). Bioinformatic
analyses of these four alleles plus the homozygous variant
identified in this study are shown in Table 1. All variants found
in ABAT deficient subjects are apparently private and were not
identified in the ExAC cohort. Additionally, all missense variants
received scores for being highly evolutionarily constrained by
GERP and PhyloP. Software prediction for the potential of
missense variants to disturb protein function assigned two of
these variants maximally ‘‘damaging’’ scores by both PolyPhen2
and SIFT. One variant received moderately damaging scores,
and one received the maximum score from PolyPhen2 but
a ‘‘tolerated’’ score from SIFT. The variant with conflicting results
from PolyPhen2 and SIFT received the most highly constrained/
conserved scores by GERP++ and PhyloP.
In order to test the functionality of specific genetic alleles, we
constructed a novel lentiviral vector (pGIPZ-GW) that, when deliv-
ered to cells, permits simultaneous expression of an individual
shRNA hairpin and an open reading frame (ORF) (i.e., cDNA) re-
combined into the Gateway (Invitrogen) ORF acceptor site (Fig-
ure 3B). This vector enables knockdown of the endogenous
wild-type copy of a gene while expressing a mutant version of
the same gene. This allows testing of pathogenic genetic alleles
in healthy control cells, alleviating the need for tissue collected
from subjects, and provides testing of those alleles in a ‘‘healthy’’
genomic context. In this case, we designed shRNAhairpins to the
30 UTRofABAT (Figures 2A and 2B) and deliveredwild-type (con-
trol) or mutant ABAT alleles (Figure 3A) into healthy fibroblasts.
Importantly, all ABAT expression constructs lacked 30 UTR
sequencemaking them resistant to shRNA-mediatedknockdown
when delivered with shRNA that targets the 30 UTR of ABAT
(Figure 3B). The functionality of each variant was tested by stable
transduction of fibroblasts and subsequent quantitation of
mtDNA copy number. Cells infected with pGIPZ-GW virus car-
rying NT shRNA and mCherry (#1) exhibited normal levels of
mtDNA as did cells expressing NT shRNA and an ORF encoding
wild-type ABAT (#3). Cells expressing ABAT-specific shRNA
and mCherry (#2) (Figure 3C) showed the same level of knock-
down of mtDNA as when the ABAT-specific shRNA is expressed
alone (50%) (Figure 2C). Co-delivery of RNAi-resistant ABAT
rescued the mtDNA depletion phenotype resulting from ABAT
shRNA (#4), allowing us to use this system to examine the efficacy
of each variant the context of wild-type ABAT depletion. Consis-
tent with their proposed roles as pathogenic variants, cells in-
fected with pGIPZ-GW virus carrying each ABATmutation in the
presence of ABAT shRNA (#5–#10) exhibit mtDNA copy numberll Metabolism 21, 417–427, March 3, 2015 ª2015 Elsevier Inc. 419
Figure 2. shRNA Knockdown of ABAT
in Healthy Fibroblasts Results in mtDNA
Depletion and Diminished Mitochondrial
Membrane Potential
(A and B) Control fibroblasts transfected with two
independent shRNAs targeting ABAT show ABAT
transcript levels that are roughly half of ABAT
transcript levels in controls (A), and western
blotting shows ABAT protein levels in these cells
are also diminshed by half (B).
(C and D) Likewise, fibroblasts with ABAT mRNA
and protein knockdown exhibit significantly di-
minshed copy number of mtDNA (C) and mem-
brane potential (D) while NT shRNA shows no
difference compared to untreated control. In all
panels, C is control, C + NT shRNA is control cells
transfected with NT shRNA, and C + ABAT shRNA
is controls cells transfected with shRNA targeting
the 30 UTR of ABAT. *** indicates p value < 1 3
105. Error bars indicate SD.similar to where the ABAT shRNA is expressed alone (#2), thus
demonstrating the inability of the alleles identified in ABAT
deficient subjects to ‘‘rescue’’ the decreased mtDNA copy num-
ber induced by knocking down the wild-type copy of ABAT pre-
sent in healthy cells. This confirms that each individual ABAT
variant found in subjectsperturbgene functionat the level of being
able to properly maintain copy number of the mitochondrial
genome.
Non-Proliferating Subject Fibroblasts Demonstrate Low
mtDNA Copy Number and Diminished Membrane
Potential, and Delivery of Wild-Type ABAT Corrects This
Mitochondrial Dysfunction
Each currently described human disease gene causing MDS is
shown in Figure 5A along with an illustration of the basic role
the protein product plays within the mitochondria. ABAT local-
izes to the mitochondrial matrix where other proteins whose
disruption leads to mtDNA depletion function in either the mito-
chondrial nucleoside salvage pathway or mtDNA replication
(Figures 5A and S2). We hypothesized that in addition to and
distinct from its recognized function catabolizing GABA, ABAT
may also play a role in one of these mitochondrial processes.
dNTPs generated in the cytosol through de novo synthesis or
salvage are utilized by the mitochondria for mtDNA mainte-
nance. However, these pathways are coordinated with the cell
cycle. When cells are in G0, nuclear DNA replication is halted
and cytosolic nucleoside pathways are downregulated, but
mitochondria continue to replicate (Pica-Mattoccia and Attardi,
1972). Consequently, in quiescent or post-mitotic cells, mito-
chondria are forced to rely on the mitochondrial nucleoside
salvage pathway to deliver nucleotides to the replicationmachin-
ery of the mitochondrial genome. In order to test our hypothesis
that ABAT participates in either mtDNA replication or nucleoside
salvage pathways, we devised a series of experiments aimed at420 Cell Metabolism 21, 417–427, March 3, 2015 ª2015 Elsevier Inc.differentiating these two functions in both
healthy and ABAT-deficient subject cells.
mtDNA copy number was determined
in subject fibroblasts while grown innormal medium (cycling cells) versus low serum medium (LSM)
(quiescent cells). Fibroblasts from subjects with ABAT mutation
(S1 and S2) have lower mtDNA copy number than controls when
grown in normal media (NM) (S1 69%, S2 82%) and decreases
when cells are grown in LSM (S1 44% of mean control; S2
55% of mean control) (Figure 4A). Likewise, their mitochondrial
membrane potential is lower than control when fibroblasts are
cycling (S1 and S2 p value < 1 3 103) and becomes more
compromised when cells are quiescent (S1 and S2 p < 1 3
105) (Figure 4B). In order to determine whether ABAT could
rescue the mtDNA copy number and membrane potential defi-
ciencies exhibited by S1- and S2-derived fibroblasts, we per-
formed gene rescue studies by stably transducing these cells
with either wild-type ABAT or vector control (GFP). As shown
in Figures 4C and 4D, delivery of wild-type ABAT corrects for
mtDNA copy number deficiency confirming that the ABAT pro-
tein plays a role in this dysfunction (S1 and S2 p < 1 3 105).
ABAT Functions in Mitochondrial Nucleoside Salvage
Pathway in the Conversion of dNDP to dNTP
The relative levels of mtDNA copy number loss in subject cells
whether cycling or quiescent are above the commonly accepted
diagnostic threshold for being reported as abnormal (%30% of
control); however, the fact that mtDNA copy number decreases
in quiescent cells supports the possibility that ABAT participates
in mitochondrial nucleoside salvage. To examine this possibility,
a series of ‘‘nucleoside rescue’’ experiments were conducted to
pinpoint if and where ABAT plays a role in the mitochondrial
nucleoside salvage pathway. Fibroblast cell lines from the two
affected siblings S1 and S2 were cultured in LSM with various
nucleotide pools: dATP+dGTP, dCTP+dTTP, dADP+dGDP,
dCDP+dTDP, dAMP+dGMP, or dCMP+dTMP. As controls, we
utilized cells from healthy individuals as well as those derived
from children who have MDS caused by pathogenic mutations
Figure 3. Pathogenic ABATMutations Iden-
tified in Subjectswith ElevatedGABA Levels
Cause a Quantitative Loss of mtDNA Copy
Number
(A) Three unrelated families have been identified
with ABAT deficiency that have a molecular diag-
nosis and elevated levels of GABA in brain
confirmed by MRS. S1 and S2 were affected sib-
lings homozygous for p.Leu211Phe (M1). S3 was
compound heterozygous for missense mutations
M2 and M3. S4 was compound heterozygous for
missense mutation M4 and deletion M5. ABAT
subject mutations are distributed throughout the
length of the protein.
(B) A first-in-kind lentiviral vector was created to
simultaneously deliver an shRNA and an ORF by
modifying the pGIPZ expression vector.
(C) Healthy cells were transduced with constructs
containing shRNA targeted to ABAT 30 UTR
and ORFs containing each subject mutation. All
mutations resulted in decreased mtDNA copy
number. *** indicates p value < 1 3 105. Error
bars indicate SD.in SUCLA2 (homozygous NP_003841.1: p.Gly424Aspfs*18) and
DGUOK (homozygous NP_550438.1 p.Phe256*) (Al-Hussaini
et al., 2014), genes known to participate in the conversion of
dNDP to dNTP and the phosphorylation of purine deoxynucleo-
sides in the mitochondria, respectively. Mouse embryonic fibro-
blasts (MEFs) derived from aSUCLA2/ gene trapmouse (Donti
et al., 2014) were also tested. Healthy cells showed the same
level of mtDNA copy number when grown in all conditions (Fig-
ure 5B). Cells from S1, S2, SUCLA2 subject, and SUCLA2/
MEFs show the same pattern of response to exposure to nucle-
osides: full rescue of mtDNA copy number when grown in the
presence of dNTPs and depletion of mtDNA under all other
growth conditions (Figure 5B). The DGUOK subject cells show
normal levels of mtDNA only when grown in the presence of de-
oxypurines. This rescue of mtDNA copy number was also suc-
cessful in cells infected with ABAT-specific shRNA (Figure 5C),
imparting additional support that providing cells with dNTPs
rescues the genetic inhibition of ABAT with regard to mtDNA
genome maintenance. This highlights that ABAT, like SUCLA2,
plays a role in the production of dNTPs in the mitochondria.
We further explored this possibility by testing if ABAT binds
to other proteins known to function at this step of the mitochon-
drial nucleoside salvage pathway, namely SUCLG1, SUCLG2,
SUCLA2, and NME4. Succinyl-CoA Synthase (SCS) is a Kreb’s
cycle enzyme that reversibly catalyzes the synthesis of succi-
nyl-CoA. SCS is a heterodimer of SUCLG1 and either SUCLG2
or SUCLA2. Children with MDS have been reported with
SUCLG1 and SUCLA2 mutations. While no patients have been
reported with SUCLG2 mutations, knockdown of SUCLG2 in
fibroblasts results in decreased mtDNA content (Miller et al.,
2011). NME4 is a mitochondrial nucleoside diphosphate kinase
(NDPK), a family of proteins known to catalyze the exchange of
g-phosphate between di- and tri-phosphonucleosides that has
been shown to associate with SCS (Kowluru et al., 2002; Tokar-Ceska-Schlattner et al., 2008). Co-immunoprecipitation studies
show that ABAT physically interacts with SUCLG1, SUCLG2,
SUCLA2, and NME4 (Figures 5D and 5E). Additionally, we
show that NME4 also binds SUCLG1, SUCLG2, and SUCLA2
(Figures 5F and 5G–5K). These experiments also confirm that
SUCLG1 and SUCLG2 bind each other while SUCLA2 binds
SUCLG1 but not SUCLG2 (Figures 5F and 5G–5I).
Pharmacological Inhibition of ABAT with Vigabatrin
Causes mtDNA Depletion in Photoreceptor Cells, which
Is Rescued by dNTP Media Supplementation
Vigabatrin is an irreversible inhibitor of ABAT that is indicated
for treatment of epilepsy. It is typically reserved for patients
who do not respond to other drugs, because up to 40% of indi-
viduals who receive vigabatrin treatment suffer retinopathy re-
sulting in visual field defects (Wild et al., 2007). Despite being
non-responsive to other AEDs, neither subject in this study
was ever treated with vigabatrin. We tested if pharmacological
inhibition of ABAT by vigabatrin causes depletion of mtDNA in
murine retinal cells. Cells were placed in G0 through growth in
LSM and cultured for 10 days with vigabatrin at doses analogous
to those given to humans, as indicated by serum concentration.
The level of mtDNA in cells showed a dose-dependent response
to vigabatrin, with an already significant drop in mtDNA at
100 mM dose, half the normal copy number of mtDNA at
200 mM, and one-third normal copy number at 300 mM (Fig-
ure 6A). Culturing cells under the same conditions but with the
addition of dNTPs to the media completely prevents any deple-
tion of mtDNA (Figure 6B).
DISCUSSION
This work demonstrates that ABAT plays an essential role in the
conversion of dNDPs to dNTPs in the mitochondrial nucleosidell Metabolism 21, 417–427, March 3, 2015 ª2015 Elsevier Inc. 421
Figure 4. G0 Fibroblasts from Subjects with
ABAT Mutations Show Deficits in mtDNA
CopyNumber andMitochondrial Membrane
Potential and Transduction with Wild-Type
ABAT cDNA Rescues Cellular Dysfunction
Fibroblasts grown in LSM enter the G0 phase of
the cell cycle and become quiescent.
(A) Subjects with ABAT mutation have lower
mtDNA copy number than controls when grown in
normal media (NM), and their mtDNA copy number
decreases to roughly half that of healthy controls
when grown in LSM.
(B) Mitochondrial membrane potential is dimin-
ished compared to controls when subject cells are
cycling and in G0.
(C and D) Subject cells transduced with wild-
type ABAT ORF (ABAT-WT) show significantly
increased mtDNA copy number (C) and mem-
brane potential (D) when compared to subject
cells transduced with GFP. Fibroblasts were
allowed to recover from lentiviral infection and
then grown in LSM for 7 days prior to harvesting for
quantitation of mtDNA. ** indicates p value < 1 3
103. *** indicates p value < 1 3 105. Error bars
indicate SD.salvage pathway and causes a neurometabolic disorder that
includes encephalomyopathic MDS. We present a new family
with ABAT deficiency and show the affected subjects have
elevated GABA in the brain as well as hallmarks of mitochondrial
dysfunction in muscle. Furthermore, we show that all ABATmu-
tations reported in humanswith elevated levels of GABA lead to a
markedmtDNA depletion in vitro. Additionally, inhibition ofABAT
through mutation, shRNA knockdown, or the drug vigabatrin
causes loss of quantitative mtDNA copy number that is rescued
by the supplementation of dNTPs.
We show that ABAT binds each of the three protein compo-
nents of SCS (SUCLG1, SUCLG2, and SUCLA2) as well as the
NDPK NME4. SCS serves as a precedent for dual-function en-
zymes that play a metabolic role in the mitochondrial matrix
and in the maintenance of mtDNA. SCS reversibly catalyzes
the synthesis of succinyl-CoA and on generation of succinate
converts GDP to GTP. Individuals with MDS can have muta-
tions in SUCLG1 and SUCLA2, but the precise role of SCS in
mtDNA maintenance remains unknown. Previous studies have
indicated an affiliation between SCS and the mitochondrial
NDPK NME4 (Kowluru et al., 2002), and in this report we
demonstrate specific binding between the individual protein
components of SCS and NME4. NME4 is the only mammalian
NDPK with a mitochondrial targeting leader sequence and
confirmed mitochondrial localization (Tokarska-Schlattner
et al., 2008), but its precise function(s) within the mitochondria
remains undetermined. While NDPKs exhibit a lack of substrate
specificity and can produce nucleoside triphosphates from all
canonical nucleoside diphosphates (Lacombe et al., 2000),
they typically utilize the phosphate from ATP to generate
dNTPs, in particular dGTP. This confirmation of physical inter-
action between SCS and NME4 supports the possible role
these two enzymes play in homeostasis of GDP/GTP and mito-
chondrial iron metabolism (Bishop et al., 2012; Gordon et al.,
2006) as well as the maintenance of mitochondrial nucleoside
pools.422 Cell Metabolism 21, 417–427, March 3, 2015 ª2015 Elsevier Inc.Nucleoside rescue studies strongly support the hypothesis
that ABAT and SCS play a role in the conversion of dNDPs to
dNTPs. We recapitulate the results of previous studies in cellular
models of DGUOK where media supplementation with dAMP
and dGMP elevates mtDNA copy number to control levels
(Saada, 2008; Taanman et al., 2003). In this study, DGUOK
serves as a control and validates our experimental approach.
Supplementation of either dA/GTP or dC/TTP but not dNDPs
rescues mtDNA copy number in multiple cellular models of
ABAT and SUCLA2 deficiency. These nucleoside rescue studies
alongside the confirmed protein interactions highlight a role for
these two proteins in the generation of dNTPs from dNDPs.
Further work is required to delineate the precise roles that
ABAT, SUCLG1, SUCLG2, and SUCLA2 each play in this
process. Similar to the findings in cellular models of TYMP defi-
ciency indicating that an insufficiency of one or more nucleo-
sides rather than an imbalance of nucleosides pools may be
the fundamental cause of depletion of mtDNA in TYMP defi-
ciency (Gonza´lez-Vioque et al., 2011), these ABAT, SUCLA2,
and DGUOK nucleoside rescue studies also lend support for
the idea that a lack of dNTPs available to the mitochondrial repli-
cation machinery causes mtDNA depletion, although more work
is needed to dissect the precise cause of mitochondrial toxicity
in vivo.
Individuals with MDS due to mutations in SUCLG1 and
SUCLA2 show some phenotypic overlap with subjects with
ABAT deficiency. SUCLG1-SUCLA2 MDS is of the encephalo-
myopathic form and manifests with clinical features that include
severe hypotonia, dystonia, developmental delay, sensorineural
hearing loss, and lactic acidosis. In contrast to SUCLA2 and
SUCLG1 patients, urine organic acids and lactate were normal
in ABAT subjects. Cultured skin fibroblasts from patients with
MDSdue toABAT,SUCLA2,SUCLG1, orDGUOK all show levels
of mtDNA within the diagnostic ‘‘normal’’ range when grown in
standard culture conditions. Likewise,measurements of electron
transport chain biochemical activity in patient fibroblasts and
Figure 5. ABAT Functions in the Conversion
of dNDP to dNTP in the Mitochondrial
Nucleoside Salvage Pathway
(A) Genes known to cause human MDSs are
shown with their function indicated as known.
(B and C) (B) Fibroblasts from two subjects
with ABAT mutations (S1 and S2) were tested
in parallel with fibroblasts from individuals with
MDS due to SUCLA2 mutation (homozygous
p.Gly424Aspfs*18), DGUOK mutation (homozy-
gous p.Phe256*), MEF from SUCLA2/ gene trap
mouse, and healthy control (C). Fibroblasts were
synchronized in G0 by growth in LSM and then
nucleosides (dNTP, dNDP, or dNMP) were added
to replica-plated cells. ABAT and SUCLA2mutant
cells show the same level of mtDNA depletion in
LSM (50%of control) and same response tomedia
nucleoside supplementation: rescue of mtDNA
depletion when either dATP/dGTP or dCTP/dTTP
are added to media.
(C) Fibroblasts transduced with ABAT shRNA
show 50% mtDNA copy number compared to
control, and this is restored to 100% of control
with media supplementation with dNTPs.
(D and E) SUCLG1, SUCLG2, SUCLA2, and NME4
participate in the conversion of dNDP to dNTP in
mitochondria. Co-IP experiments show that ABAT
binds all four of these proteins.
(F–K) Additionally, each possible pairwise binding
between SUCLG1, SUCLG2, SUCLA2, and NME4
was tested. SUCLG1 binds SUCLG2, SUCLA2,
and NME4. SUCLG2 binds NME4 but not
SUCLA2. SUCLA2 also binds NME4. *** indicates
p value < 1 3 105. Error bars indicate SD.in healthy fibroblasts transduced with shRNA targeting ABAT
show some appreciable deficiencies, but none outside the diag-
nostic normal range (Figure S4). Once cells are induced into
quiescence through growth in LSM, patient fibroblasts harboring
ABAT, SUCLA2, and DGUOK mutations show marked mtDNA
depletion with 50% of normal copy number (SUCLG1 patient
cells were not available for testing). Hence, in fibroblasts from
MDS subjects with mutations in genes involved in mitochondrial
nucleoside metabolism, the mtDNA copy number is not suffi-
ciently low to be classed as ‘‘definitively defective’’ within a diag-
nostic setting, but a significant decrease is observed between
cycling and quiescent cells. This is consistent with ABAT, SCS,
and DGUOK being essential for the mitochondrial nucleoside
salvage pathway, which is primarily utilized during G0 when
cytosolic nucleoside salvage pathways are downregulated.
The most common human inborn error of metabolism in
the GABA degradation pathway is succinic semialdehyde dehy-
drogenase deficiency (SSADHD) (OMIM #271980), an autosomal
recessive disorder characterized by mutations in ALDH5A1Cell Metabolism 21, 417–4leading to the elevation of g-hydroxybu-
tyric acid (GHB) and GABA (Chambliss
et al., 1998). Clinical presentation of
SSADHD overlaps with ABAT deficiency
and includes developmental delay, hypo-
tonia, hyporeflexia, ataxia, and seizures
(Knerr et al., 2007). Individuals withABAT mutations may appear similar to more severe cases of
SSADHD, and it is important to note these two disorders can
be distinguished through measurement of GHB, which is not
elevated in ABAT deficiency.
Our findings reveal ABAT to be an enzyme of dual function, its
deficiency leading to a neurometabolic disorder as well as a loss
of mtDNA copy number. Given the phenotypic overlap between
neurometabolic disorders and primary mitochondrial disorders,
it is difficult to ascribe which pathological process, depletion
of ATP or disrupted GABA metabolism, is largely responsible
for the clinical and diagnostic observations. For example,
measurement of respiratory chain biochemical activities in mus-
cle showed multiple respiratory chain complex abnormalities,
including loss of complex II activity. This enzyme is encoded
solely by nuclear genes, and consequently, a decrease inmtDNA
copy number would not be expected to affect this activity. The
fact that complex II activity is decreased in subjects with ABAT
mutation suggests factors outside of decreased mtDNA copy
number contribute to OXPHOS dysfunction in muscle, but it27, March 3, 2015 ª2015 Elsevier Inc. 423
Figure 6. Pharmacological Inhibition of ABAT with Vigabatrin
Causes mtDNA Depletion in Photoreceptor Cells That Is Rescued
by Media Supplementation with dNTPs
(A and B) (A) Photoreceptor cells were grown in the presence of Vigabatrin in
varying doses (0–300 mM) and (B) Vigabatrin plus dNTPs. *** indicates p value <
1 3 105. Error bars indicate SD.does not necessarily indicate that mtDNA depletion is not
contributing to the loss of enzyme activity or that disturbance
of GABA catabolism directly causes loss of complex II activity.
Nevertheless, our data clearly demonstrate an essential role for
ABAT in the conversion of dNDP to dNTP within mitochondria,
and as such patients with pathogenic ABAT mutations should
be classed as having both a neurometabolic disorder and a dis-
order of mtDNA copy number maintenance. The discovery that
ABAT plays an essential role in nucleoside metabolism may
reveal insights into the mechanism underlying the retinal defects
often observed in individuals receiving vigabatrin treatment. In
cellular models, we observed half the normal copy number of
mtDNA at 200 mM dose of vigabatrin (Figure 6), which falls within
the serum levels corresponding to the dosage range adminis-
tered to adults (Lindberger et al., 2003). This same reduction of
mtDNA copy number is seen in fibroblasts from subjects with
ABAT mutations, as well as individuals with mutations in
SUCLA2 or DGUOK andMEFs from SUCLA2/mouse (Figures
4 and 5). Remarkably, this depletion is completely prevented by
co-treatment of cells with vigabatrin plus dNTPs. Vigabatrin
exposure would be expected to result in undesired effects in tis-
sues that rely most heavily on the mitochondrial nucleoside
pathway, like eye and brain. However, additional factors influ-
ence the effects of vigabatrin on specific tissues, and conse-
quently, any undesired effects due to loss of mtDNA copy num-
ber would not necessarily be expected to be the same across all
non-cycling tissues. For example, vigabatrin concentration has424 Cell Metabolism 21, 417–427, March 3, 2015 ª2015 Elsevier Inc.been shown in animal models to accumulate 18.5 times higher
in retina than brain (Sills et al., 2003). Taken together, this work
reveals a potential cause for the visual field defects commonly
occurring with vigabatrin treatment and indicates nucleosides
as having therapeutic potential to prevent this side effect.
ABATdeficiency causesmtDNAdepletion syndromeaswell as
a neurometabolic disorder of GABA degradation that shares
phenotypic overlap with individuals with mutations in SUCLG1,
SUCLA2, and ALDH5A1. This work places ABAT in a key role in
mitochondrial nucleoside metabolism and identifies SUCLG1,
SUCLG2, SUCLA2, and NDPK as protein interactors for ABAT.
It will be important to learn if the catabolism of GABA by ABAT
is coordinated with the production of dNTPs in the mitochondria
and if modulation of dNTP levels accessible to mitochondria can
be achieved as a therapeutic for individuals with deficiency in this
pathway whether genetically or pharmacologically induced.
EXPERIMENTAL PROCEDURES
Subjects
Subjects 1 and 2 are affected siblings in a family of Mexican origin. The family
self-reports distant consanguinity of unspecified relationship. Informed con-
sent was obtained for all subjects approved by local Institutional Review
Boards. Genomic DNA was extracted from cultured fibroblasts according to
standard protocols.
Proton Magnetic Resonance Spectroscopy
Protonmagnetic resonance spectroscopy (1H-MRS) was obtained using a sin-
gle-voxel stimulated-echo acquisition mode (SV-STEAM) sequence (Frahm
et al., 1987) (TE/TR = 20/2,000ms) on a 3T Philips Achieva (Best, Netherlands).
Post-processing was performed using LCModel, version 6.1-4, to quantify the
spectra (Provencher, 1993). Region of interest was placed at the level of the
basal ganglia: LCModel output of in vivo 1H-MRS region of interest volume,
10–17.5 ml; TE/TR, 20–30/2,000 ms; number of averages 128.
Mitochondrial Respiratory Chain Activity Assays
The activities of individual respiratory chain complexes weremeasured in skel-
etal muscle homogenates and cultured fibroblasts as described previously
(Kirby et al., 2007). Enzymatic activity is expressed relative to citrate synthase
and is shown as a percentage of normal controls.
Identification, Verification, and Annotation of Subject Mutations
S1 was sequenced by whole-exome capture using VCROME capture assay
(Bainbridge et al., 2011). Sequence data were aligned, single nucleotide vari-
ants (SNVs) and small insertions and deletions (InDels) were called by GATK
(DePristo et al., 2011), and quality control filtering of variants was based on
coverage, strand bias, mapping quality, and base quality. Custom Perl scripts
were used to annotate variants. Several metrics for prediction of potential
functional consequences of variants were applied: SIFT (Ng and Henikoff,
2001) and PolyPhen2 (Adzhubei et al., 2010), GERP (Davydov et al., 2010),
and PhyloP (A. Siepel et al., 2006, RECOMB, conference). Filtering of variants
included five criteria: (1) allele frequencymust be less than 1% in any reference
population. (2) PhyloP must be greater than two OR GERP greater than five or
maximum damaging scores for SIFT or PolyPhen2. (3) Variants should be ho-
mozygous or compound heterozygous. (4) Variants must not be present in a
segmental duplication. (5) Variant must not be present in a SNP cluster defined
as the presence of five or more SNVs within 1 Kb of each other. The Exome
Aggregation Consortium (ExAC) Cohort was used as reference population
data for variant filtering of exome data and for checking the allele frequency
of ABAT variants in found in subjects with ABAT deficiency (Exome Aggrega-
tion ConsortiumCohort, Cambridge) (http://exac.broadinstitute.org, accessed
November, 2014).
The ABAT variant identified through exome sequencing in S1 was orthogo-
nally validated, and recessive segregation through the subject’s pedigree was
confirmed with Sanger sequencing.
All genetic alleles studied were submitted to ClinVar http://www.ncbi.nlm.
nih.gov/clinvar/ and were annotated in reference to ABAT NM_000663.4 for
cDNA and NP_000654.2 for protein.
Primary Fibroblast Cell Culture
Human and mouse embryonic fibroblasts were grown in MEM (Life Technolo-
gies) supplemented with FBS to 10%, 13 MEM-vitamins, 2 mM L-glutamine,
1 mM sodium pyruvate, 13 penicillin/streptomycin, 13 non-essential amino
acids, and 0.41 mM uridine.
shRNA Knockdown of ABAT
Oligonucleotides containing shRNA hairpins that target the 30 UTR of ABAT
were custom designed and cloned into the pGIPZ vector (GE Healthcare).
Control fibroblasts were infected with two independent shRNA hairpins plus
a scrambled shRNA, and 72 hr post-infection QRT-PCR and western blot for
ABAT were performed on these cells as described below.
Quantitation of mtDNA Copy Number
Mitochondrial genome copy number was determined by real-time quantitative
PCR as described previously (Bonnen et al., 2013). Briefly, the mitochondrial
genome copy number is determined relative to the nuclear genome using
theMTND1 region of mitochondrial genome and B2M as the nuclear genome
normalizer. The assay utilized iTaqTM SYBR Green Supermix with ROX (Bio-
Rad Laboratories, Hercules, CA) and was conducted in triplicate on total
genomic DNA and shown as the average and SD.
Assessment of Mitochondrial Membrane Potential
Mitochondrial membrane potential was assessed as previously described
(Bonnen et al., 2013). Cells were grown to confluence, counted, and then
were either stained directly with DilC1(5) or pre-incubated with carbonyl cya-
nide 3-chlorophenylhydrazone (CCCP) prior to staining (MitoProbe DilC1(5)
Assay kit for Flow Cytometry, Life Technologies). Results are reported as the
difference between themean fluorescence intensity (MFI) of cells that received
treatment with CCCP versus those that did not. Assays were conducted in trip-
licate and shown as the average and SD.
Quantitation of ABAT mRNA by qRT-PCR
RNA was extracted and cDNA synthesized using standard protocols. Quanti-
tative real-time PCR experiments were performed using a StepOne Plus
RT-PCR system (Applied Biosystems), RT2 qPCR Primer Assays for Human
GAPDH and ABAT (SABiosciences), and PerfeCTa SYBR Green FastMix
ROX (Quanta Biosciences). The cycle of threshold value (Ct) was normalized
to the transcripts for the housekeeping gene GAPDH. All assays were con-
ducted in triplicate and the results are shown as the average and SD.
Vector Construction for pGIPZ-GW
The pGIPZ-GW vector, which allows simultaneous expression of ORF and
shRNA, was generated by introducing a Gateway cloning cassette and pre-
ceding CMV promoter generated using the Fusion HD Cloning Kit (Clontech)
and the vector pLenti6.3 V5/DEST (Life Technologies) as PCR template into
the pGIPZ vector restriction digested with XbaI/BsrGI.
Cloning and Functionally Testing ABAT Mutations
Wild-type ABAT entry ORF clone (NM_000663.3; clone ID: IOH13638) was ob-
tained from Invitrogen. ABAT mutant ORFs were constructed by site-directed
mutagenesis using the wild-type ORF template and the following mutant PCR
primers:
M1(ORF631C > T; L211F):ctgccccgactacagcatcTtctccttcatgggcgcgttcca
tgggagga;
M2(ORF659G > A; R220K):atgggcgcgttccatgggaAgaccatgggttgcttagcgac
cacgcactc;
M3(ORF1433T > C; L478P):attcgtttccgtcccacgcCggtcttcagggatcaccacgc
tcacctgtt;
M4(ORF 275G > A; R92Q):gttgatgtggacggcaaccAaatgctggatctttattcccag
atctcctc).
ORFs were recombined into destination vector (pLex302) with LR recombi-
nase (Invitrogen). Mutation M5 (Q66 del) was generated by PCR using ABAT-
specific primers fused to attB1/B2 recombination sequences (Invitrogen)Cedesigned following the manufacture’s recommendations, followed by recom-
bination of the PCR product into entry vector (pDONR221; Invitrogen) with
BP recombinase (Invitrogen) for subsequent delivery to destination vector as
specified above.
shRNA hairpins that target the ABAT 30 UTR and a scrambled shRNA were
transferred from the pGIPZ vector into the pGIPZ-GW by enzymatic digestion
(XhoI + MluI) and ligation. Then the cDNAs corresponding to mCherry, ABAT
wild-type, or ABAT mutants were transferred from Donor223 vector (Invitro-
gen) into the pGIPZ-GW by LR recombination reaction (Invitrogen).
Virus production was conducted as previously described (Bonnen et al.,
2013). Infectious lentiviral supernatant was used to infect healthy growing
fibroblasts with polybrene (Sigma) before selection by puromycin.
Gene Rescue
Patient and control fibroblasts were stably infected with a pLX302 lentiviral
mammalian expression vector system expressing EGFP and ABAT cDNA
(NM_000663.4) as previously described (Bonnen et al., 2013).
Nucleotide Rescue
Healthy, patient, and mouse embryonic fibroblasts were seeded at a concen-
tration of 50,000 cells per well and grown in DMEM (Thermo Scientific Hyclone)
with 15% FBS (Atlanta Biologicals) until reaching confluence. The growth me-
dium was then removed, and the cells were washed three times with 13 PBS.
LSM (DMEM with 0.5% FBS) was added and the cells cultured for 24 hr. Sub-
sequently, LSM was replaced with fresh LSM containing either dNMP, dNDP,
or dNTP (Sigma-Aldrich) each at a final concentration of 50 mM. Cells were
cultured under these conditions for 7 days and then harvested.
Fibroblast cell lines used as controls in this experiment included an individ-
ual with MDS due to homozygous SUCLA2 NP_003841.1: p.Gly424Aspfs*18
mutation and a subject who is homozygous for DGUOK NP_550438.1
p.Phe256* (Al-Hussaini et al., 2014) (OMIM #612073 and OMIM #251880).
An additional control was mouse embryonic fibroblasts from a SUCLA2/
gene trap mouse (Donti et al., 2014).
Co-Immunoprecipitation and Western Blotting
Proteins of interest (ABAT, SUCLG1, SUCLG2, SUCLA2, and NME4) were
tagged with HA and Myc tags by PCR reaction using primers that contained
Gateway Cloning attB sites to facilitate insertion of the PCR products into
Donor223 vector (Invitrogen). Tagged proteins were next transferred by LR
recombination reaction into a mammalian expression vector pLenti6.3/V5-
Dest vector (Invitrogen).
HEK293T cells were transfected with tagged proteins using Lipofectamine
2000 (Invitrogen) and harvested 48 hr after transfection. For immunoprecipita-
tion, equivalent amounts of cell lysates were incubated with primary anti-HA
rabbit/mouse (Cell Signaling) or anti-Myc rabbit/mouse (Cell Signaling)
antibodies for 2 hr. Then, a 50% slurry of protein A/G-sepharose was added
and incubated for 1 hr. Whole-cell extracts and immunoprecipitates were
resolved on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to Immobilon P PVDFmembranes (Millipore). Membranes were im-
munoblotted overnight at 4C with the indicated antibodies followed by sec-
ondary antibody (Santa Cruz Biotechnology) and visualized using Enhanced
Chemiluminescence Western Blotting System (GE Healthcare).
Cellular and Sub-Mitochondrial Fractionation for Localization
of ABAT
Subcellular fractionswere prepared as described previously (Bruni et al., 2013)
with few modifications. HEK293 cells were harvested, resuspended in HB
(0.6 M Mannitol, 10 mM Tris-HCl [pH 7.4], and 1 mM EGTA), and subjected
to standard differential centrifugation, and the post-mitochondrial supernatant
(cytosolic fraction) was retained. To obtain sub-mitochondrial fractions, 650 mg
of mitochondria were treated with proteinase K (PK), pelleted and resus-
pended in HB. Mitoplasts were obtained by resuspending PK-treated
mitochondria in 10mM Tris-HCl and treated with PK. To extract the inner mito-
chondrial membrane (IMM) proteins, PK-treated mitoplasts were pelleted,
and the pellet was dissolved in 100 mM Na2CO3 and incubated on ice for
30 min. This was centrifuged at 100,000 3 g for 15 min at 4C, and the pellet
was dissolved in HB. Proteins (40 mg) from whole-cell lysate, cytosolic, and
mitochondrial fractions were loaded onto 12% SDS-PAGE gel, transferredll Metabolism 21, 417–427, March 3, 2015 ª2015 Elsevier Inc. 425
to PVDFmembrane, and immunoblotted with primary antibodies to eIF4E (Cell
Signaling), AIF (NEB), GDH (custom made), NDUFA9 (Mitosciences), and
ABAT (Abcam).
Vigabatrin Studies in Mouse Photoreceptor Cells
Cells from the immortalizedmurine retinal cone photoreceptor-derived cell line
(661W) were seeded at a concentration of 200,000 cells per well and grown in
DMEM (Thermo Scientific Hyclone) with 10% FBS (Atlanta Biologicals) until
near confluence. The growth medium was then removed, and the cells were
washed three times with 13 PBS. LSM (DMEM with 0.5% FBS) was added
and the cells were cultured for 24 hr. Next, LSM was replaced with fresh
LSM containing 50 mM dNTP (Sigma-Aldrich) and vigabatrin (Sigma-Aldrich)
at 100, 150, 200, or 300 mM. Media was replaced every day until day 10,
when cells were harvested.
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